(NASDAQ: INBX) Inhibrx Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 22.32%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 57.17%.
Inhibrx Biosciences's earnings in 2025 is $1,722,971,000.On average, 1 Wall Street analyst forecast INBX's earnings for 2025 to be -$168,933,800, with the lowest INBX earnings forecast at -$168,933,800, and the highest INBX earnings forecast at -$168,933,800.
In 2026, INBX is forecast to generate -$123,045,184 in earnings, with the lowest earnings forecast at -$123,045,184 and the highest earnings forecast at -$123,045,184.